OTCMKTS:CVSI - CV Sciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding CV Sciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.56 -0.02 (-3.48 %) (As of 04/2/2020 02:36 PM ET) Add Compare Today's Range$0.53Now: $0.56▼$0.5850-Day Range$0.29MA: $0.68▼$0.9452-Week Range$0.25Now: $0.56▼$6.21Volume293,328 shsAverage Volume930,263 shsMarket Capitalization$55.71 millionP/E RatioN/ADividend YieldN/ABeta0.43 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email CV Sciences, Inc. operates as a life science company. It operates through two segments, Consumer Products and Specialty Pharmaceuticals. The Consumer Products segment manufactures, markets, and sells consumer products containing hemp-based cannabidiol oil under the PlusCBD brand in various market sectors, including nutraceutical, beauty care, specialty foods, and vape. This segment provides its hemp extract products in balms, sprays, drops, capsules, gummies, and softgel forms. It also sells raw materials to various customers that produce products for resale into the market in Europe. The Specialty Pharmaceuticals segment develops cannabinoids to treat a range of medical indications. Its product candidate is CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was founded in 2010 and is based in Las Vegas, Nevada.Read More Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:CVSI Previous SymbolNASDAQ:CVSI CUSIPN/A CIK1510964 Webhttp://www.cvsciences.com/ Phone866-290-2157Debt Debt-to-Equity Ratio0.29 Current Ratio2.99 Quick Ratio2.16Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$53.70 million Price / Sales1.04 Cash Flow$0.11 per share Price / Cash Flow5.23 Book Value$0.31 per share Price / Book1.79Profitability EPS (Most Recent Fiscal Year)($0.17) Net Income$-16,610,000.00 Net Margins-30.93% Return on Equity-50.64% Return on Assets-31.74%Miscellaneous Employees78 Outstanding Shares100,380,000Market Cap$55.71 million Next Earnings Date5/13/2020 (Estimated) OptionableNot Optionable Receive CVSI News and Ratings via Email Sign-up to receive the latest news and ratings for CVSI and its competitors with MarketBeat's FREE daily newsletter. OTC:CVSI Rates by TradingView CV Sciences (OTCMKTS:CVSI) Frequently Asked Questions How has CV Sciences' stock been impacted by COVID-19 (Coronavirus)? CV Sciences' stock was trading at $0.60 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CVSI stock has decreased by 7.5% and is now trading at $0.5550. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of CV Sciences? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CV Sciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for CV Sciences. When is CV Sciences' next earnings date? CV Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for CV Sciences. How were CV Sciences' earnings last quarter? CV Sciences Inc (OTCMKTS:CVSI) posted its quarterly earnings data on Tuesday, May, 15th. The company reported $0.01 earnings per share for the quarter. The firm had revenue of $8.07 million for the quarter. CV Sciences had a negative net margin of 30.93% and a negative return on equity of 50.64%. View CV Sciences' earnings history. What price target have analysts set for CVSI? 4 Wall Street analysts have issued 1-year target prices for CV Sciences' shares. Their forecasts range from $4.20 to $9.00. On average, they anticipate CV Sciences' stock price to reach $6.55 in the next year. This suggests a possible upside of 1,080.2% from the stock's current price. View analysts' price targets for CV Sciences. Has CV Sciences been receiving favorable news coverage? Media stories about CVSI stock have been trending very negative on Thursday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. CV Sciences earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutCV Sciences. Who are some of CV Sciences' key competitors? Some companies that are related to CV Sciences include Aduro BioTech (ADRO), AMAG Pharmaceuticals (AMAG), Lexicon Pharmaceuticals (LXRX), MannKind (MNKD), OptiNose (OPTN), Protagonist Therapeutics (PTGX), Arcturus Therapeutics (ARCT), Recro Pharma (REPH), XOMA (XOMA), Selecta Biosciences (SELB), NuCana (NCNA), Gemphire Therapeutics (GEMP), IVERIC bio (ISEE), MEI Pharma (MEIP) and Abeona Therapeutics (ABEO). What other stocks do shareholders of CV Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other CV Sciences investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Cronos Group (CRON), Charlotte's Web (CWBHF), Aphria (APHA), KushCo (KSHB), OrganiGram (OGI), GW Pharmaceuticals PLC- (GWPH), Tilray (TLRY) and Medical Marijuana (MJNA). Who are CV Sciences' key executives? CV Sciences' management team includes the following people: Mr. Joseph D. Dowling, CEO, Sec. & Director (Age 62)Mr. Michael J. Mona III, Co-Founder, COO & Director (Age 33)Mr. Joerg Grasser, CFO, Chief Accounting Officer & DirectorDr. Joseph Maroon, MD & DirectorDr. Douglas MacKay ND, Sr. VP of Scientific & Regulatory Affairs and Director What is CV Sciences' stock symbol? CV Sciences trades on the OTCMKTS under the ticker symbol "CVSI." How do I buy shares of CV Sciences? Shares of CVSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is CV Sciences' stock price today? One share of CVSI stock can currently be purchased for approximately $0.56. How big of a company is CV Sciences? CV Sciences has a market capitalization of $55.71 million and generates $53.70 million in revenue each year. The company earns $-16,610,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis. CV Sciences employs 78 workers across the globe. View additional information about CV Sciences. What is CV Sciences' official website? The official website for CV Sciences is http://www.cvsciences.com/. How can I contact CV Sciences? CV Sciences' mailing address is 10070 BARNES CANYON ROAD, SAN DIEGO CA, 92121. The company can be reached via phone at 866-290-2157 or via email at [email protected] MarketBeat Community Rating for CV Sciences (OTCMKTS CVSI)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 206 (Vote Outperform)Underperform Votes: 178 (Vote Underperform)Total Votes: 384MarketBeat's community ratings are surveys of what our community members think about CV Sciences and other stocks. Vote "Outperform" if you believe CVSI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CVSI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/2/2020 by MarketBeat.com StaffFeatured Article: Certificate of Deposit (CD) For Risk Adverse Investors?
